Social Responsibility

Sustainable Development

Public welfare activity

Focusing on Advances in Orthopedics: Xianshi Pharmaceutical Presents Core Products at Yunnan Provincial Orthopedic Academic Conference

Focusing on Advances in Orthopedics: Xianshi Pharmaceutical Presents Core Products at Yunnan Provincial Orthopedic Academic Conference

KUNMING, Nov 06, 2025 — The 11th Yunnan Medical Association Orthopedics Academic Conference (3rd Session) recently concluded at Kunming Yun’an Convention Center. Organized by the Orthopedics Branch of Yunnan Medical Association and co-hosted by top local hospitals, the event gathered leading orthopedic experts and frontline clinicians to share cutting-edge surgical technologies, innovative diagnosis and treatment plans, and the latest industry development trends.

→

View Details

11-06

2025

Four pharmaceutical companies in the Liuyang Economic Development Zone have eight drugs proposed for inclusion in the 11th round of national centralized procurement.

Four pharmaceutical companies in the Liuyang Economic Development Zone have eight drugs proposed for inclusion in the 11th round of national centralized procurement.

Changsha Evening News, Changsha on the Go, October 31 (All‑media reporter Zhu Zehuan, correspondent Hu Jixing) — Recently, the results of the 11th round of national centralized bulk procurement of drugs were announced, with 55 medications selected. These cover commonly used medicines in areas such as anti‑infection, anti‑allergy, anti‑tumor, blood‑sugar‑lowering, blood‑pressure‑lowering, lipid‑lowering, and anti‑inflammatory/analgesic treatments. A total of 453 products from 272 enterprises nationwide have been granted preliminary eligibility for selection. In the Liuyang Economic Development Zone, four pharmaceutical companies have a combined eight drug products slated to be included in the 11th round of national centralized procurement.

→

View Details

10-31

2025

Three Products of Hunan Xianshi Pharmaceutical Selected in China’s 11th National Volume-Based Drug Procurement

Three Products of Hunan Xianshi Pharmaceutical Selected in China’s 11th National Volume-Based Drug Procurement

CHANGSHA, Oct 28, 2025 — The preliminary winning list of the 11th round of China’s National Volume-Based Drug Procurement was released on October 27. Three core pharmaceutical products developed by Hunan Xianshi Pharmaceutical Co., Ltd., namely Procaterol Hydrochloride Inhalation Solution, Avatrombopag Maleate Tablets and Roxadustat Capsules, have been shortlisted in the program. The achievement recognizes the company’s product quality and R&D strength, and marks key progress in improving affordable medicine accessibility for domestic patients.

→

View Details

10-28

2025

[Exhibition Recap] Hunan Xianshi Pharmaceutical Concludes Successful Participation at CPHI China 2025

[Exhibition Recap] Hunan Xianshi Pharmaceutical Concludes Successful Participation at CPHI China 2025

SHANGHAI, June 30, 2025 — CPHI China 2025, the three-day World Pharmaceutical Ingredients Exhibition, wrapped up at Shanghai New International Expo Center from June 24 to 26. As a reliable supplier specializing in APIs, pharmaceutical intermediates and excipients, Hunan Xianshi Pharmaceutical Co., Ltd. presented its core products and newly developed innovations at Booth E12D76, Hall E1. The company attracted wide attention and conducted in-depth communications with global clients and industrial counterparts.

→

View Details

06-30

2025

Hunan TV Reports on Xianshi Pharmaceutical’s Intelligent Oseltamivir Phosphate Granule Production Line

Hunan TV Reports on Xianshi Pharmaceutical’s Intelligent Oseltamivir Phosphate Granule Production Line

CHANGSHA, Feb 14, 2025 — Hunan Xianshi Pharmaceutical Co., Ltd. is accelerating digital transformation and smart manufacturing development amid national low-carbon and new-industry policy initiatives. On February 13, Hunan TV covered the company’s intelligent production line for oseltamivir phosphate granules during a live news report.

→

View Details

02-14

2025

< 123 >